80099-46-3

Basic information

• Product Name: ethyl 2-[4-(2-bromoacetyl)phenoxy]-propanoate
• Synonyms: ethyl 2-[4-(2-bromoacetyl)phenoxy]-propanoate
• CAS NO: 80099-46-3
• Molecular Weight: 315.164
• Mol File: 80099-46-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: ethyl 2-[4-(2-bromoacetyl)phenoxy]-propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-[4-(2-bromoacetyl)phenoxy]-propanoate(80099-46-3)
• EPA Substance Registry System: ethyl 2-[4-(2-bromoacetyl)phenoxy]-propanoate(80099-46-3)

Safety Data

• Hazardous Substances Data: 80099-46-3(Hazardous Substances Data)

Upstream product

• 96928-09-5 ethyl 2-(4-acetylphenoxy)-propanoate 
• 91143-71-4 (RS)-2-(4-acetylphenoxy)propionic acid 
• 42412-84-0 ethyl 2-phenoxypropionate 
• 598-21-0 2-Bromoacetyl bromide 

Downstream Products

• 96928-23-3 2-[4-(2-Phenyl-thiazol-4-yl)-phenoxy]-propionic acid ethyl ester 
• 1113057-22-9 ethyl 2-{4-[2-(5-(2,3-dicarbobenzoxy-1-guanidino)-1-oxo-2,3-dihydro-1H-benzo[c]azol-2-yl)acetyl]phenoxy}-propanoate 
• 96928-29-9 2-{4-[2-(4-Methoxy-phenylamino)-thiazol-4-yl]-phenoxy}-propionic acid 
• 96928-30-2 2-{4-[2-(4-Chloro-phenylamino)-thiazol-4-yl]-phenoxy}-propionic acid 
• 96928-28-8 2-[4-(2-p-Tolylamino-thiazol-4-yl)-phenoxy]-propionic acid 
• 96928-27-7 2-[4-(2-Phenylamino-thiazol-4-yl)-phenoxy]-propionic acid 
• 96928-34-6 2-{4-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-phenoxy}-propionic acid 
• 96928-33-5 2-[4-(2-p-Tolyl-thiazol-4-yl)-phenoxy]-propionic acid 
• 96928-32-4 2-[4-(2-Phenyl-thiazol-4-yl)-phenoxy]-propionic acid 
• 96928-26-6 2-[4-(2-Amino-thiazol-4-yl)-phenoxy]-propionic acid 
• 96928-31-3 2-propionic acid 
• 96928-21-1 2-{4-[2-(4-Chloro-phenylamino)-thiazol-4-yl]-phenoxy}-propionic acid ethyl ester 
• 96928-18-6 2-[4-(2-Phenylamino-thiazol-4-yl)-phenoxy]-propionic acid ethyl ester 
• 96928-20-0 2-{4-[2-(4-Methoxy-phenylamino)-thiazol-4-yl]-phenoxy}-propionic acid ethyl ester 

Relevant articles and documents

Stereospecific synthesis and bio-activity of novel β3-adrenoceptor agonists and inverse agonists

Since it is widely distributed into the body, β3-adrenoceptor is becoming an attractive target for the treatment of several pathologies such as obesity, type 2 diabetes, metabolic syndrome, cachexia, overactive bladder, ulcero-inflammatory disorder of the gut, preterm labour, anxiety and depressive disorders, and heart failure. New compounds belonging to the class of arylethanolamines bearing one or two stereogenic centres were prepared in good yields as racemates and optically active forms. They were, then, evaluated for their intrinsic activity towards β3-adrenoceptor and their affinity for β1- and β2-adrenergic receptors. Stereochemical features were found to play a crucial role in determining the behaviour of such compounds. In particular, α-racemic, (αR)- and (αS)-2-{4-[2-(2-hydroxy-2-phenylethylamino)ethyl]phenoxy}-2- methylpropanoic acid, (α-rac, β-rac)-, (αR, βS)- and (αR, βR)- 2-{4-[2-(2-hydroxy-2-phenylethylamino)ethyl]phenoxy}propanoic acid were found to be endowed with β3-adrenoceptor agonistic activity. Whereas, (αS, βS)- and (αS, βR)-2-{4-[2-(2-hydroxy-2-phenylethylamino)ethyl]phenoxy}propanoic acid behaved as β3-adrenoceptor inverse agonists. Such compounds showed no affinity for β1- and β2-adrenergic receptor, respectively. Thus, resulting highly selective β3-adrenoceptor ligands.

Synthesis and Mass Spectral Studies of Some Thiazolylphenoxypropionic Acids and Esters

Several 2- and 3-propionic acids (III and IV) have been prepared by the reaction of the corresponding phenacyl bromides with thioureas and thioamides (Hantzsch synthesis).The mass spectra of the esters (II) of III show a unique fragmentation resulting in the concerted loss of CH3CHO and CH3CH=C=O from the molecular ion through a rearrangement involving transfer of a hydrogen atom from ethyl group to the phenoxy oxygen.Another hydrogen transfer reaction leads to the concerted loss of CO2 and C2H4 from the molecular ion of IV.However, no such process is observed in the mass spectra of III.The thiazole ring suffers cleavage in a characteristic manner after the removal of acid/ester function in II, III and IV.The compounds have been screened for their antiinflammatory activity.